The European Commission has granted marketing authorization for Nulibry for injection as the first therapy for the treatment of patients with molybdenum cofactor deficiency
The European Commission (EC) has granted marketing authorization for Nulibry (fosdenopterin) for Injection as the first therapy for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A
The drug is being developed by US biotech BridgeBio Pharma and Sentynl Therapeutics, a USA-based subsidiary of India’s Zydus Lifesciences
MoCD Type A is an ultra-rare and progressive condition known to impact less than 150 patients globally with a median survival of four years.
Nulibry is a first-in-class cPMP substrate replacement therapy that was approved by the FDA in 2021 to reduce the risk of mortality in patients with MoCD Type A. Following this decision by the EC, Nulibry is the first and only approved therapy in the European Union (EU) for MoCD Type A.
Related news and insights
Biogen Inc.announced the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for review of tofersen, an investigational drug for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). SOD1-ALS is a progressive and uniformly fatal disease that affects less than 1,000 people in Europe
Eli Lilly announced updated results from the pivotal Phase III monarchE trial of adjuvant Verzenio (abemaciclib) in combination with standard endocrine therapy (ET) for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, high risk early breast cancer (EBC)